NCT06572618View on ClinicalTrials.gov

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

January 8, 2027

Study Completion Date

January 8, 2027

Conditions
Mantle Cell Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Nemtabrutinib

Given PO

PROCEDURE

Positron Emission Tomography and Computed Tomography Scan

Undergo PET-CT scan

BIOLOGICAL

Rituximab

Given IV

Trial Locations (2)

91010

RECRUITING

City of Hope Medical Center, Duarte

92618

NOT_YET_RECRUITING

City of Hope at Irvine Lennar, Irvine

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER